Alonso Ricardo files SEC Form 4 disclosures for Ra Pharmaceuticals, Inc.. They have made 6 open-market trades across 1 company since 2019, most recently 2020-04-02.
CIK 0001768722
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RARX | 2,288 | $110K |
Shares reported on the most recent Form 4, priced at the 2020-01-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RARX | SELL | 2020-03-17 | 2020-03-18 | $44.25 | $101K | +16.9% | N/A | N/A |
| RARX | SELL | 2020-01-17 | 2020-01-21 | $47.02 | $215K | -0.1% | -0.3% | N/A |
| RARX | SELL | 2019-12-17 | 2019-12-18 | $47.08 | $215K | +0.0% | +0.1% | -4.6% |
| RARX | SELL | 2019-10-17 | 2019-10-17 | $46.70 | $213K | -0.2% | +0.0% | +0.6% |
| RARX | SELL | 2019-08-23 | 2019-08-27 | $27.89 | $127K | -8.2% | -8.9% | +70.8% |
| RARX | SELL | 2019-06-21 | 2019-06-25 | $23.72 | $136K | +16.5% | +31.9% | -5.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.